Company · CIK 0001806310 · SIC 2836 — Biological Products, (No Diagnostic Substances) · Nasdaq
Taysha Gene Therapies, Inc. · TSHA
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 10, 2026 SForm 4 → | Jul 10, 6:54 pm EDT | Sukumar NagendranPresident and Head of R&D, Director | 200,000 | $6.24 | $1,248,000 | 936,410 | −17.6% | 10b5-1 |
Reported at this company — derivatives (options, RSUs, warrants)
No reported derivative activity in this period.